Top

Published in:

01-02-2011 | Letter

Extraperitoneal rectal cancer: why laparoscopic may be more effective than open surgery

Authors: John Spiliotis, Odysseas Zoras

Published in: Surgical Endoscopy | Issue 2/2011

Excerpt

In the August 2009 issue of Surgical Endoscopy, Park et al. [1] provide clinically important comparative-effectiveness information on laparoscopic versus open surgery for extraperitoneal rectal carcinoma. Comparative-effectiveness research (CER) is the current standard strategy to draw robust conclusions on new drugs, medical devices, and surgical techniques [2]. Phase III randomized controlled trials are the best tools for ultimate decisions in medicine. …

Park IJ, Choi GS, Lim KH, Kang BM, Jun SH (2009) Laparoscopic resection of extraperitoneal rectal cancer: a comparative analysis with open resection. Surg Endosc 23(8):1818–1824CrossRefPubMed

Garber AM, Tunis SR (2009) Does comparative-effectiveness research threaten personalized medicine? N Engl J Med 360(19):1925–1927CrossRefPubMed

Kuhry E, Schwenk W, Gaupset R, Romild U, Bonjer J (2008) Long-term outcome of laparoscopic surgery for colorectal cancer: a Cochrane systematic review of randomised controlled trials. Cancer Treat Rev 34(6):498–504CrossRefPubMed

Ziogas D, Polychronidis A, Kanellos I, Roukos DH (2009) Laparoscopic colectomy survival benefit for colon cancer: is evidence from a randomized trial true? Ann Surg 249(4):695–696 (author reply 697)CrossRefPubMed

Liakakos T, Roukos DH (2009) Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. Ann Surg 250(2):349–350CrossRefPubMed

Liakakos T, Roukos D (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 22(6):1553–1555CrossRefPubMed

Roukos DH (2009) Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg 250:650–651CrossRef

Ziogas D, Roukos D (2009) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc 22(5):1405–1406CrossRef

Kappas AM, Roukos DH (2002) Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol 9(9):828–830CrossRefPubMed

10.

Roukos DH, Paraschou P, Lorenz M (2000) Distal gastric cancer and extensive surgery: a new evaluation method based on the study of the status of residual lymph nodes after limited surgery. Ann Surg Oncol 7(10):719–726CrossRefPubMed

11.

Roukos DH (2009) Personalized cancer diagnostics and therapeutics. Expert Rev Mol Diagn 9(3):227–229CrossRefPubMed

12.

Roukos DH (2009) Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn 9(3):217–221CrossRefPubMed

13.

Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249(6):1067–1068CrossRefPubMed

14.

Ziogas D, Roukos DH (2009) Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol 16(7):1771–1782CrossRefPubMed

15.

Roukos DH (2009) Genome-wide association studies: how predictable is a person’s cancer risk? Expert Rev Anticancer Ther 9(4):389–392CrossRefPubMed

16.

Roukos DH (2009) Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol 27(8):1337–1338CrossRefPubMed

17.

Roukos DH (2009) Radiation therapy for breast cancer. N Engl J Med 360(13):1362 (author reply 1363)CrossRefPubMed

18.

Roukos DH (2008) Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev Mol Diagn 8(5):587–597CrossRefPubMed

19.

Roukos DH, Lykoudis E, Liakakos T (2009) Genomics and challenges toward personalized breast cancer local control. J Clin Oncol 26(26):4360–4361CrossRef

20.

Roukos DH (2009) Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol 16(3):772–773CrossRefPubMed

21.

Roukos DH, Ziogas D (2009) Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the “Gordian knot”? Ann Surg Oncol 16(3):774–775CrossRefPubMed

22.

Roukos DH (2008) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 358(2):197 (author reply 198)CrossRefPubMed

23.

Roukos DH (2008) Breast-cancer stromal cells with TP53 mutations. N Engl J Med 358(15):1636PubMed

24.

Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10(2):123–128CrossRefPubMed

25.

Roukos DH (2008) Linking contralateral breast cancer with genetics. Radiother Oncol 86:139–141CrossRefPubMed

26.

Roukos DH (2007) Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357(2):1555–1556PubMed

27.

Roukos DH (2009) Assessing both genetic variation (SNPs/CNVs) and gene-environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn 9(1):1–6CrossRefPubMed

28.

Roukos DH (2010) Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol 17:14–17CrossRefPubMed

29.

Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16(10):2678–2681CrossRefPubMed

30.

Roukos DH (2010) Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 10(3):247–250CrossRefPubMed

31.

Roukos DH (2010) Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. J Clin Oncol 28(17):e279–e280CrossRefPubMed

32.

Roukos DH (2010) Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11(3):283–287CrossRefPubMed

33.

Roukos DH (2010) Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn 10(1):33–48CrossRefPubMed

34.

Roukos DH (2009) Isolated tumor cells in breast cancer. N Engl J Med 361:1994–1995CrossRefPubMed

35.

Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 9(10):1413–1416CrossRefPubMed

Title: Extraperitoneal rectal cancer: why laparoscopic may be more effective than open surgery
Authors: John Spiliotis
Odysseas Zoras
Publication date: 01-02-2011
Publisher: Springer-Verlag
Published in: Surgical Endoscopy / Issue 2/2011
Print ISSN: 0930-2794
Electronic ISSN: 1432-2218
DOI: https://doi.org/10.1007/s00464-010-1232-6

At a glance: The STEP trials

Springer Medicine

Extraperitoneal rectal cancer: why laparoscopic may be more effective than open surgery

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2011

Long-term follow-up of laparoscopic repair of parastomal hernia using a bilayer mesh with a slit

Endoscopic mucosal resection for gastroesophageal cancer in a U.K. population. Long-term follow-up of a consecutive series

Laparoscopic versus open techniques in rectal cancer surgery: a retrospective analysis of 121 sphincter-saving procedures in a single institution

Laparoscopic enucleation of pancreatic neoplasm

Conversion after laparoscopic cholecystectomy in England